ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 000C19

Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease

Identifieur interne : 000C19 ( PascalFrancis/Corpus ); précédent : 000C18; suivant : 000C20

Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease

Auteurs : Caroline Perlemoine ; Frédéric Macia ; Francois Tison ; Isabelle Coman ; Dominique Guehl ; Pierre Burbaud ; Emmanuel Cuny ; Laurence Baillet ; Henri Gins ; Vincent Rigalleau

Source :

British Journal of Nutrition [ 0007-1145 ] ; 2005.

RBID : Pascal:06-0038622

Descripteurs français

Pascal (Inist)
- Noyau sousthalamique, Energie, Taux production, Substrat, Oxydation, Dépense énergétique, Poids, Changement, Parkinson maladie, Régime alimentaire, Thermogenèse, Mammalia.

English descriptors

KwdEn :
- Change, Diet, Energetic cost, Energy, Mammalia, Oxidation, Parkinson disease, Production rate, Substrate, Subthalamic nucleus, Thermogenesis, Weight.

Abstract

Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0007-1145`
A03		`1`		`@0 Br. J. Nutr.`
A05				`@2 93`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease`
A11	`01`	`1`		`@1 PERLEMOINE (Caroline)`
A11	`02`	`1`		`@1 MACIA (Frédéric)`
A11	`03`	`1`		`@1 TISON (Francois)`
A11	`04`	`1`		`@1 COMAN (Isabelle)`
A11	`05`	`1`		`@1 GUEHL (Dominique)`
A11	`06`	`1`		`@1 BURBAUD (Pierre)`
A11	`07`	`1`		`@1 CUNY (Emmanuel)`
A11	`08`	`1`		`@1 BAILLET (Laurence)`
A11	`09`	`1`		`@1 GINS (Henri)`
A11	`10`	`1`		`@1 RIGALLEAU (Vincent)`
A14	`01`			`@1 Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan @2 33600 Pessac @3 FRA @Z 1 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut.`
A14	`02`			`@1 Service de Neurologie, Hôpital Haut-Lévêque @2 Pessac @3 FRA @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A14	`03`			`@1 Service de Neurochirurgie, Hôpital du Tripode @2 Bordeaux @3 FRA @Z 7 aut.`
A20				`@1 191-198`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 2404 @5 354000125987450050`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 06-0038622`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 British Journal of Nutrition`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.
C02	`01`	`X`		`@0 002A16E`
C03	`01`	`X`	`FRE`	`@0 Noyau sousthalamique @5 01`
C03	`01`	`X`	`ENG`	`@0 Subthalamic nucleus @5 01`
C03	`01`	`X`	`SPA`	`@0 Núcleo subtalámico @5 01`
C03	`02`	`X`	`FRE`	`@0 Energie @5 02`
C03	`02`	`X`	`ENG`	`@0 Energy @5 02`
C03	`02`	`X`	`SPA`	`@0 Energía @5 02`
C03	`03`	`X`	`FRE`	`@0 Taux production @5 03`
C03	`03`	`X`	`ENG`	`@0 Production rate @5 03`
C03	`03`	`X`	`SPA`	`@0 Índice producción @5 03`
C03	`04`	`X`	`FRE`	`@0 Substrat @5 04`
C03	`04`	`X`	`ENG`	`@0 Substrate @5 04`
C03	`04`	`X`	`SPA`	`@0 Substrato @5 04`
C03	`05`	`X`	`FRE`	`@0 Oxydation @5 05`
C03	`05`	`X`	`ENG`	`@0 Oxidation @5 05`
C03	`05`	`X`	`SPA`	`@0 Oxidación @5 05`
C03	`06`	`X`	`FRE`	`@0 Dépense énergétique @5 06`
C03	`06`	`X`	`ENG`	`@0 Energetic cost @5 06`
C03	`06`	`X`	`SPA`	`@0 Costo energético @5 06`
C03	`07`	`X`	`FRE`	`@0 Poids @5 07`
C03	`07`	`X`	`ENG`	`@0 Weight @5 07`
C03	`07`	`X`	`SPA`	`@0 Peso @5 07`
C03	`08`	`X`	`FRE`	`@0 Changement @5 08`
C03	`08`	`X`	`ENG`	`@0 Change @5 08`
C03	`08`	`X`	`SPA`	`@0 Cambio @5 08`
C03	`09`	`X`	`FRE`	`@0 Parkinson maladie @5 09`
C03	`09`	`X`	`ENG`	`@0 Parkinson disease @5 09`
C03	`09`	`X`	`SPA`	`@0 Parkinson enfermedad @5 09`
C03	`10`	`X`	`FRE`	`@0 Régime alimentaire @5 10`
C03	`10`	`X`	`ENG`	`@0 Diet @5 10`
C03	`10`	`X`	`SPA`	`@0 Régimen alimentario @5 10`
C03	`11`	`X`	`FRE`	`@0 Thermogenèse @5 11`
C03	`11`	`X`	`ENG`	`@0 Thermogenesis @5 11`
C03	`11`	`X`	`SPA`	`@0 Termogénesis @5 11`
C03	`12`	`X`	`FRE`	`@0 Mammalia @2 NS @5 13`
C03	`12`	`X`	`ENG`	`@0 Mammalia @2 NS @5 13`
C03	`12`	`X`	`SPA`	`@0 Mammalia @2 NS @5 13`
C07	`01`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`01`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`01`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`02`	`X`	`FRE`	`@0 Encéphale pathologie @5 20`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 20`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 20`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central @5 21`
C07	`03`	`X`	`ENG`	`@0 Central nervous system @5 21`
C07	`03`	`X`	`SPA`	`@0 Sistema nervioso central @5 21`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 22`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 22`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 22`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 23`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 23`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 23`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 24`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 24`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 24`
C07	`07`	`X`	`FRE`	`@0 Système nerveux pathologie @5 25`
C07	`07`	`X`	`ENG`	`@0 Nervous system diseases @5 25`
C07	`07`	`X`	`SPA`	`@0 Sistema nervioso patología @5 25`
C07	`08`	`X`	`FRE`	`@0 Alimentation @5 26`
C07	`08`	`X`	`ENG`	`@0 Feeding @5 26`
C07	`08`	`X`	`SPA`	`@0 Alimentación @5 26`
N21				`@1 016`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0038622 INIST
ET :	Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease
AU :	PERLEMOINE (Caroline); MACIA (Frédéric); TISON (Francois); COMAN (Isabelle); GUEHL (Dominique); BURBAUD (Pierre); CUNY (Emmanuel); BAILLET (Laurence); GINS (Henri); RIGALLEAU (Vincent)
AF :	Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan/33600 Pessac/France (1 aut., 8 aut., 9 aut., 10 aut.); Service de Neurologie, Hôpital Haut-Lévêque/Pessac/France (2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Service de Neurochirurgie, Hôpital du Tripode/Bordeaux/France (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	British Journal of Nutrition; ISSN 0007-1145; Royaume-Uni; Da. 2005; Vol. 93; No. 2; Pp. 191-198; Bibl. 31 ref.
LA :	Anglais
EA :	Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.
CC :	002A16E
FD :	Noyau sousthalamique; Energie; Taux production; Substrat; Oxydation; Dépense énergétique; Poids; Changement; Parkinson maladie; Régime alimentaire; Thermogenèse; Mammalia
FG :	Vertebrata; Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Alimentation
ED :	Subthalamic nucleus; Energy; Production rate; Substrate; Oxidation; Energetic cost; Weight; Change; Parkinson disease; Diet; Thermogenesis; Mammalia
EG :	Vertebrata; Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Feeding
SD :	Núcleo subtalámico; Energía; Índice producción; Substrato; Oxidación; Costo energético; Peso; Cambio; Parkinson enfermedad; Régimen alimentario; Termogénesis; Mammalia
LO :	INIST-2404.354000125987450050
ID :	06-0038622

Links to Exploration step

Pascal:06-0038622

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease</title>
<author><name sortKey="Perlemoine, Caroline" sort="Perlemoine, Caroline" uniqKey="Perlemoine C" first="Caroline" last="Perlemoine">Caroline Perlemoine</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macia, Frederic" sort="Macia, Frederic" uniqKey="Macia F" first="Frédéric" last="Macia">Frédéric Macia</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="Francois" last="Tison">Francois Tison</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coman, Isabelle" sort="Coman, Isabelle" uniqKey="Coman I" first="Isabelle" last="Coman">Isabelle Coman</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guehl, Dominique" sort="Guehl, Dominique" uniqKey="Guehl D" first="Dominique" last="Guehl">Dominique Guehl</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burbaud, Pierre" sort="Burbaud, Pierre" uniqKey="Burbaud P" first="Pierre" last="Burbaud">Pierre Burbaud</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cuny, Emmanuel" sort="Cuny, Emmanuel" uniqKey="Cuny E" first="Emmanuel" last="Cuny">Emmanuel Cuny</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neurochirurgie, Hôpital du Tripode</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baillet, Laurence" sort="Baillet, Laurence" uniqKey="Baillet L" first="Laurence" last="Baillet">Laurence Baillet</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gins, Henri" sort="Gins, Henri" uniqKey="Gins H" first="Henri" last="Gins">Henri Gins</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rigalleau, Vincent" sort="Rigalleau, Vincent" uniqKey="Rigalleau V" first="Vincent" last="Rigalleau">Vincent Rigalleau</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0038622</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 06-0038622 INIST</idno>
<idno type="RBID">Pascal:06-0038622</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease</title>
<author><name sortKey="Perlemoine, Caroline" sort="Perlemoine, Caroline" uniqKey="Perlemoine C" first="Caroline" last="Perlemoine">Caroline Perlemoine</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Macia, Frederic" sort="Macia, Frederic" uniqKey="Macia F" first="Frédéric" last="Macia">Frédéric Macia</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="Francois" last="Tison">Francois Tison</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Coman, Isabelle" sort="Coman, Isabelle" uniqKey="Coman I" first="Isabelle" last="Coman">Isabelle Coman</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Guehl, Dominique" sort="Guehl, Dominique" uniqKey="Guehl D" first="Dominique" last="Guehl">Dominique Guehl</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burbaud, Pierre" sort="Burbaud, Pierre" uniqKey="Burbaud P" first="Pierre" last="Burbaud">Pierre Burbaud</name>
<affiliation><inist:fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cuny, Emmanuel" sort="Cuny, Emmanuel" uniqKey="Cuny E" first="Emmanuel" last="Cuny">Emmanuel Cuny</name>
<affiliation><inist:fA14 i1="03"><s1>Service de Neurochirurgie, Hôpital du Tripode</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baillet, Laurence" sort="Baillet, Laurence" uniqKey="Baillet L" first="Laurence" last="Baillet">Laurence Baillet</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gins, Henri" sort="Gins, Henri" uniqKey="Gins H" first="Henri" last="Gins">Henri Gins</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rigalleau, Vincent" sort="Rigalleau, Vincent" uniqKey="Rigalleau V" first="Vincent" last="Rigalleau">Vincent Rigalleau</name>
<affiliation><inist:fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">British Journal of Nutrition</title>
<title level="j" type="abbreviated">Br. J. Nutr.</title>
<idno type="ISSN">0007-1145</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">British Journal of Nutrition</title>
<title level="j" type="abbreviated">Br. J. Nutr.</title>
<idno type="ISSN">0007-1145</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Change</term>
<term>Diet</term>
<term>Energetic cost</term>
<term>Energy</term>
<term>Mammalia</term>
<term>Oxidation</term>
<term>Parkinson disease</term>
<term>Production rate</term>
<term>Substrate</term>
<term>Subthalamic nucleus</term>
<term>Thermogenesis</term>
<term>Weight</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Noyau sousthalamique</term>
<term>Energie</term>
<term>Taux production</term>
<term>Substrat</term>
<term>Oxydation</term>
<term>Dépense énergétique</term>
<term>Poids</term>
<term>Changement</term>
<term>Parkinson maladie</term>
<term>Régime alimentaire</term>
<term>Thermogenèse</term>
<term>Mammalia</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0007-1145</s0>
</fA01>
<fA03 i2="1"><s0>Br. J. Nutr.</s0>
</fA03>
<fA05><s2>93</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PERLEMOINE (Caroline)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MACIA (Frédéric)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>TISON (Francois)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>COMAN (Isabelle)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GUEHL (Dominique)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BURBAUD (Pierre)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CUNY (Emmanuel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BAILLET (Laurence)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GINS (Henri)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>RIGALLEAU (Vincent)</s1>
</fA11>
<fA14 i1="01"><s1>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan</s1>
<s2>33600 Pessac</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Service de Neurologie, Hôpital Haut-Lévêque</s1>
<s2>Pessac</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Service de Neurochirurgie, Hôpital du Tripode</s1>
<s2>Bordeaux</s2>
<s3>FRA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>191-198</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>2404</s2>
<s5>354000125987450050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0038622</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>British Journal of Nutrition</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A16E</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Noyau sousthalamique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Subthalamic nucleus</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Núcleo subtalámico</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Energie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Energy</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Energía</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Taux production</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Production rate</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Índice producción</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Substrat</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Substrate</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Substrato</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Oxydation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Oxidation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Oxidación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Dépense énergétique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Energetic cost</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Costo energético</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Poids</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Weight</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Peso</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Changement</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Change</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cambio</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Régime alimentaire</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Diet</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Régimen alimentario</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Thermogenèse</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Thermogenesis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Termogénesis</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>20</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>21</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>22</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>23</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>24</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>25</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Alimentation</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Feeding</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Alimentación</s0>
<s5>26</s5>
</fC07>
<fN21><s1>016</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0038622 INIST</NO>
<ET>Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease</ET>
<AU>PERLEMOINE (Caroline); MACIA (Frédéric); TISON (Francois); COMAN (Isabelle); GUEHL (Dominique); BURBAUD (Pierre); CUNY (Emmanuel); BAILLET (Laurence); GINS (Henri); RIGALLEAU (Vincent)</AU>
<AF>Service de Nutrition-Diabétologie, Hôpital Haut-Lévêque, Avenue Magellan/33600 Pessac/France (1 aut., 8 aut., 9 aut., 10 aut.); Service de Neurologie, Hôpital Haut-Lévêque/Pessac/France (2 aut., 3 aut., 4 aut., 5 aut., 6 aut.); Service de Neurochirurgie, Hôpital du Tripode/Bordeaux/France (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>British Journal of Nutrition; ISSN 0007-1145; Royaume-Uni; Da. 2005; Vol. 93; No. 2; Pp. 191-198; Bibl. 31 ref.</SO>
<LA>Anglais</LA>
<EA>Patients with Parkinson's disease (PD) often lose weight, but after subthalamic nucleus deep brain stimulation (STN-DBS), they gain weight. We compared daily energy intake (DEI), resting energy expenditure (REE) and substrate oxidation rates (measured by indirect calorimetry) in nineteen STN-DBS-treated patients (Group S), thirteen others on pharmacologic treatment by levodopa (Group L) and eight control subjects. We also determined the acute effects of STN-DBS and levodopa on REE and substrate oxidation rates. STN-DBS treated patients gained 9.7 (SEM 7.1) kg after surgery, whereas patients on pharmacologic treatment lost 3.8 (SEM 10.0) kg since diagnosis. In STN-DBS-treated patients, REE (-16.5%; P<0.001), lipid oxidation (-27%; P<0.05) and protein oxidation (-46 %; P<0.05) were decreased, whereas glucose oxidation was elevated (+81 %; P<0.05) as compared to patients on pharmacologic treatment. Levodopa acutely reduced REE (-8.3%; P<0.05) and glucose oxidation (-37 %; P<0.01) with a slight hyperglycaemic effect (after levodopa challenge: 5.6 (SEM 0.8) v. before levodopa challenge: 5.3 (SEM 0.6) mmol/l; P<0.01). Switching 'on' STN-DBS acutely reduced REE (- 17.5%; P<0.01) and lipid oxidation (-24%; P<0◦.001) 30 min after starting stimulation. Fasting glycaemia was slightly but significantly reduced (5.4 (SEM 1-4) v. 5.5 (SEM 1.3) mmol/1; P<0.01). After STN-DBS, the normalization of REE and the reduction in lipid and protein oxidation contribute to the restoration of weight. As levodopa decreases glucose oxidation, the reduction in daily dose of levodopa in STN-DBS-treated patients helps prevent the effect of weight gain on glycaemia.</EA>
<CC>002A16E</CC>
<FD>Noyau sousthalamique; Energie; Taux production; Substrat; Oxydation; Dépense énergétique; Poids; Changement; Parkinson maladie; Régime alimentaire; Thermogenèse; Mammalia</FD>
<FG>Vertebrata; Encéphale pathologie; Système nerveux central; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie; Alimentation</FG>
<ED>Subthalamic nucleus; Energy; Production rate; Substrate; Oxidation; Energetic cost; Weight; Change; Parkinson disease; Diet; Thermogenesis; Mammalia</ED>
<EG>Vertebrata; Cerebral disorder; Central nervous system; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases; Feeding</EG>
<SD>Núcleo subtalámico; Energía; Índice producción; Substrato; Oxidación; Costo energético; Peso; Cambio; Parkinson enfermedad; Régimen alimentario; Termogénesis; Mammalia</SD>
<LO>INIST-2404.354000125987450050</LO>
<ID>06-0038622</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0038622
   |texte=   Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease

Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri